Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Extends Delay In Returning Some OTCs To Market

This article was originally published in The Tan Sheet

Executive Summary

CFO Caruso says operating under a consent decree with “a third party in the manufacturing facilities with us” makes it “very difficult for us to predict exactly when products will return.” Some products will not return to stores until 2013, significantly later than the original goal to relaunch all recalled liquid OTCs before 2012.

You may also be interested in...



Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”

The most popular stories in “The Tan Sheet” during 2012 dealt with FDA’s nonprescription safe use regulatory extension initiative, as well as planned switches by Pfizer and Merck. In dietary supplements, coverage of firms struggling with GMPs and congressional threats to DSHEA drew the most interest.

Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”

The most popular stories in “The Tan Sheet” during 2012 dealt with FDA’s nonprescription safe use regulatory extension initiative, as well as planned switches by Pfizer and Merck. In dietary supplements, coverage of firms struggling with GMPs and congressional threats to DSHEA drew the most interest.

FDA Flags J&J For Inadequate Oversight Of Consumer Devices

FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, including K-Y moisturizers, after finding shortcomings in post-market monitoring and pre-market notification. The agency’s May 22 warning letter does not cite manufacturing issues.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel